We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 432

Why Biotech And Pharma Patents Survive IPR
  • Pepper Hamilton LLP
  • USA
  • November 21 2018

When the America Invents Act of 2011 ushered in a number of new administrative procedures for challenging issued patents, the biotechnology and


Delaware Found to be Improper Venue for ANDA Suit
  • Dechert LLP
  • USA
  • October 31 2018

The District of Delaware dismissed a Hatch-Waxman Act ANDA lawsuit that Bristol-Myers Squibb had filed against Mylan Pharmaceuticals, finding that


FDA’S Clarification of 180-Day Exclusivity Rules
  • Cozen O'Connor
  • USA
  • August 23 2018

On July 13, 2018, the FDA issued a letter to ANDA applicants for buprenorphine and naloxone sublingual film that has application beyond that drug


Proposed Legislation: The Hatch-Waxman Integrity Act
  • Knobbe Martens
  • USA
  • July 23 2018

Senator Orrin Hatch (R-UT) recently introduced a bill titled the “Hatch-Waxman Integrity Act of 2018” (HWIA). Sen. Hatch suggests that the HWIA will


Hatch Bill: Restore Hatch-Waxman Balance; Limit Generics’ Access to PTAB
  • Jones Day
  • USA
  • July 1 2018

Senator Orrin Hatch (R-Utah), the namesake and coauthor of the Hatch-Waxman Act, proposed (but has not yet introduced) an amendment titled the


Choose Your Weapon: Senate Amendment Pits ANDABPCIA Pathway Against Post-Grant Proceedings
  • Seyfarth Shaw LLP
  • USA
  • June 26 2018

Per Senator Orrin Hatch, the America Invents Act has disrupted the “careful balance” he struck with Senator Waxman in the development of the


FTC Says Hatch-Waxman Suits Not Immune from Antitrust Scrutiny
  • Vinson & Elkins LLP
  • USA
  • June 26 2018

The Federal Trade Commission (“FTC”) has sought permission to file an amicus brief in a pharmaceutical patent case, urging a district court to reject


Personalized Medicine Gets a Boost from Federal Circuit’s Vanda Pharma Decision - PART II: Enforcement
  • Mintz
  • USA
  • April 30 2018

The Federal Circuit’s decision in Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. (2016-2707, 2016-2708 April 13, 2018) provided some good news on


A U.S. Perspective on Global Strategy
  • Sterne Kessler Goldstein & Fox PLLC
  • USA, Taiwan
  • April 13 2018

In December 2017, the Taiwan Pharmaceutical Affairs Act has been amended to harmonize generic approval process with prevailing international norms


Orange Book-Listed Patents Challenged in AIA Trial Proceedings
  • Buchanan Ingersoll & Rooney PC
  • USA
  • March 22 2018

The USPTO recently issued a study concerning AIA trial proceedings challenging Orange Book-Listed patents.1 The study was presented by the PTAB in a